Why the study?
Cardiovascular risk increases even within the normal blood pressure range, but the efficacy of vitamins and minerals for lowering blood pressure in the general normotensive population was unclear.
Do vitamins and minerals (Vitamins C, D, E; Calcium, Magnesium, Potassium) reduce systolic and diastolic blood pressure in the general, normotensive population?
Do vitamins and minerals (Vitamins C, D, E; Calcium, Magnesium, Potassium) reduce systolic and diastolic blood pressure in the general, normotensive population?
Supplementation with calcium, magnesium, potassium, and vitamin E may provide modest blood pressure reductions in normotensive individuals.
Some nutraceuticals modestly lower BP in normotensives; extends prior evidence and supports dosing trials before routine use.
Hypertension is the leading preventable risk factor for cardiovascular disease and all-cause mortality worldwide. However, studies have shown increased risk of mortality from heart disease and stroke even within the normal blood pressure (BP) range, starting at BPs above 110-115/70-75 mm Hg. Nutraceuticals, such as vitamins and minerals, have been studied extensively for their efficacy in lowering BP and may be of benefit to the general, normotensive population in achieving optimal BP. Our study investigated the effects of six nutraceuticals (Vitamins: C, D, E; Minerals: Calcium, Magnesium, Potassium) on both systolic blood pressure (SBP) and diastolic blood pressure (DBP) in this population. We performed a systematic review and pairwise meta-analysis for all six supplements versus placebo. Calcium and magnesium achieved significant reductions in both SBP and DBP of -1.37/-1.63 mm Hg and -2.79/-1.56 mm Hg, respectively. Vitamin E and potassium only yielded significant reductions in SBP with values of -1.76 mm Hg and -2.10 mm Hg, respectively. Vitamins C and D were not found to significantly lower either SBP or DBP. Future studies should determine optimal dosage and treatment length for these supplements in the general, normotensive population.
No takes yet. Share an insight, caveat, or question.
Behers et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: